Provista Blog > What Are Breast Cancer Biomarkers?
Despite recent advances in breast imaging technologies, the ability to accurately detect breast cancer remains challenging. As a result, patients and their healthcare providers can be left with uncertainty around their annual imaging resutls. This leads to situations where patients are either under or over treated, which adds uncertainty and extra costs to patients and healthcare providers. As a result, we need a diagnostic tool to complement imaging when results are hard to interpret.
Innovations in science and cancer research have allowed us to detect cancer at the cellular level by identifying breast cancer protein biomarkers in the blood. Proteomic technologies can identify changes in protein signatures in the blood specific to breast cancer. It detects the absence of disease related biomarkers in real time. To learn more about this process, check out this informational video about proteomic advances in cancer detection:
To improve patient outcomes and detect breast cancer as early as possible we must use ProteoMark technology, which allows us to gain reliable protein signatures in the blood. This technology analyzes two types of biomarkers; Serum Protein Biomarkers (SPBs) and Tumor-Associated Autoantibodies (TAAbs) and allows us to rule out and detect breast cancer in patients independent of anatomy, family history and biopsy.
TAAbs are the body's immune response that are released into the bloodstream when the presence of tumor proteins are detected. TAAbs are stable, highly specific and easily detected in serum.
SPBs are produced either by the host, surrounding environment or tumor including proteins involved in, but not limited to, inflammation, angiogenesis and cell growth. In the presence of cancer, these processes can aid in tumor development and/or progression.
It has been conclusively demonstrated that by including both SPBs and TAAbs within the same signature, we are able to capture cancer signals from eight of the ten "Hallmarks of Cancer." To learn more about the utilization of SPBs and TAAbs, read our study published in PLOS One here. This comprehensive approach is the key to improving breast cancer detection.
At Provista Diagnostics, our mission is to develop world-class diagnostic tests for indications in breast and gynecologic cancers. As a leading diagnostics company, our aim is to create, produce and market innovative solutions for unmet clinical needs. Our products and services help to diagnose diseases and inform better clinical decisions, thus enhancing women’s health and quality of life. We do this in a responsible and ethical manner with a commitment to excellence in every aspect of our business.